• Parexel Acquisition, Medable Expands to Europe, NSF Funds for RWE Outcomes

    Aug 03 | Clinical Research News | Parexel acquired by private equity business, American Heart Association seeks genomic diversity, partnerships for Flywheel and HealthMyne as well as Marken and THREAD. More
  • Patient-Centric Focus, Awareness, Technology Can Fix Pharma’s Lack of Progress on Trial Diversity

    Jul 30 | Clinical Research News | Conversations of diversity in clinical trials has been just talk for a long time. It’s great that study results are being reported with demographic data about race and ethnicity, but it’s still up to the individual pharma company whether it wants to report diversity or not. This is not the path toward meaningful change. More
  • Machine Learning Can Predict If COVID-19 Trials Will Succeed

    Jul 29 | Clinical Research News | A pair of computer scientists at Florida Atlantic University have come up with a machine learning approach to predict the likelihood of a clinical trial being terminated down the road and attribute factors contributing to study termination or success. When applied to the flurry of COVID-19 trials launched since early last year it performs particularly well. More
  • Data Privacy And Patient-Centeredness Driving Technology Adoption

    Jul 26 | Clinical Research News | The potential of artificial intelligence (AI), internet-connected devices, wearables, and cloud computing to disrupt traditional clinical trials was explored during a presentation on patient-centered endpoints at the recent DIA 2021 Global Annual Meeting. The common goal is to make studies more palatable for participants, improving their engagement and retention, and to help pick up the pace and cost of making new medicines. More
  • 5 Reasons Why a Decentralized Method Works for Clinical Trials

    Jul 23 | Clinical Research News | With sponsors like IQVIA, Pfizer, and GSK joining the Decentralized Trials & Research Alliance and the FDA giving decentralization its nod of approval, it’s safe to say the clinical research industry will continue to embrace decentralized trials. More
  • Building Trust In Real-World Evidence

    Jul 21 | Clinical Research News | Lessons learned to date about the growing use of real-world evidence (RWE), including emerging approaches to improve study design and the measurement of treatment effects, were highlighted during a presentation by regulatory and pharmacoepidemiology (PE) experts at the recent DIA 2021 Global Annual Meeting. The wide-ranging conversation touched on everything from the regulatory context in which RWE is being used and whether clinical questions can be reliably addressed to the quality of real-world data (RWD) sources and more rigorous methodological approaches that might be adopted to help ensure confidence in study findings. More
  • Overcoming Barriers To Using Artificial Intelligence In Clinical Research

    Jul 20 | Clinical Research News | Current and potential uses of artificial intelligence (AI) and automation in clinical research, and ways to overcome common barriers, were discussed by a panel of industry experts at the recent DIA 2021 Global Annual Meeting. Two multi-stakeholder communities of practice groups now meet regularly to explore ways to leverage AI and machine learning (ML), one focused on improving trial quality and cycle times and the other producing high-quality protocols and reducing risks before the start of a study. More
  • MedVector To Connect Patients Of Local Physicians To Study Investigators

    Jul 19 | Clinical Research News | A startup is positioning itself to be a key player in the burgeoning decentralized clinical trial (DCT) marketplace and has tapped industry innovator Craig Lipset, who designed and co-led the industry’s first fully virtual clinical trial, to be its executive advisor. MedVector is the first company to enable local, non-investigative physicians to access clinical trial medications as a care alternative. More
  • The Ultimate Patient-Centric Supply Chain

    Jul 16 | Clinical Research News | A supply chain strategy that truly puts patients at the center requires a wide variety of trial services, delivered seamlessly. Improved patient access, reliability, customizability—all these things are incompatible with fragmented service and require the central coordination and end-to-end oversight only available from a comprehensive, single-source solutions provider. More
  • Studies Using External Control Arms Gaining Ground

    Jul 16 | Clinical Research News | The willingness of healthcare authorities to accept external control arms (ECAs) in regulatory submissions depends largely on how and when they are used, according to real-world data (RWD) experts from Merck, Bristol-Myers Squibb, and Ikaika Health who presented at the recent DIA 2021 Global Annual Meeting. More
View more articles

DIA NOW is the source for life science knowledge. Comprehensive and customizable, and backed by DIA's extensive history, global reach, and experience, you'll stay on top of trends and receive up-to-the-minute updates on a wide variety of critical issues in the life sciences arena. Get your one-month free trial today!